S-1/A: Ludwig Enterprises Files S-1/A for Public Offering

Ludwig Enterprises, an early-stage genomics company, filed an S-1/A for a public offering to fund its operations and advance its non-invasive breast cancer diagnostic test, despite significant losses and going concern doubts.

Summary

• Ludwig Enterprises, Inc. is an early-stage genomics-based diagnostic company focused on developing tests for inflammation-related chronic diseases, including cancers.
• The company intends to launch its initial product, the Revealia™ Breast test, a non-invasive cheek swab assay for breast cancer detection, by the end of Q4 2025.
• The S-1/A filing is for a firm commitment public offering of Common Stock, contingent on a reverse stock split (1-for-50 to 1-for-250) and listing on a national exchange.
• The company has not sold any products to date and has incurred significant net losses: $1,190,387 for the six months ended June 30, 2025, and $3,016,884 for the year ended December 31, 2024.
• As of June 30, 2025, the company had a working capital deficit of $3,402,780 and an accumulated deficit of $8,449,753, raising substantial doubt about its ability to continue as a going concern.
• Proceeds from the offering are estimated to be approximately $ after deducting underwriting discounts and expenses, and will be used for equipment, marketing, staffing, legal/accounting, company awareness, R&D, debt repayment, and stock repurchase options.
• The offering price will be negotiated between the company and the underwriter, ThinkEquity LLC, and is subject to market conditions.
• Existing Convertible Preferred Stock will automatically convert into 700,000,000 shares of Common Stock upon the offering's effectiveness, and $ of accrued interest and original issuance discounts from Convertible Notes will convert into Common Stock.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position, marked by significant accumulated losses, a substantial working capital deficit, and an explicit 'going concern' warning from its auditors. While it has an innovative product pipeline and a clear strategy, the lack of revenue, dependence on future capital raises, and high execution risks for an early-stage company warrant a very low sentiment score. The offering itself is critical for survival, not for growth from a position of strength.

Positives

• The company is developing an innovative non-invasive mRNA-based diagnostic test (Revealia™ Breast) for early detection of inflammation-related chronic diseases, including cancer.
• Preliminary validation studies for Revealia™ Breast showed promising results with 92% sensitivity, 54% specificity, 86% negative predictive value, and an AUC of 76%, comparing favorably to mammography benchmarks.
• The technology platform is designed to be scalable and adaptable to other inflammation-driven conditions beyond oncology, such as cardiovascular and neurodegenerative disorders.
• The company has filed provisional patent application #63/689422 for its proprietary mRNA storage technology and has two patent families covering diagnostic tests for various cancers in multiple global jurisdictions.
• New independent directors, Garth Lees-Rolfe and Corain McGinn, have been appointed, bringing extensive experience in finance, biotech, and technology/pharmaceutical sectors.
• The company has a clear commercialization model combining direct-to-consumer sales with laboratory partnerships and plans to pursue reimbursement from commercial insurers and public payors in the long term.

Negatives

• The company is an early-stage genomics technology company with no products or services currently available for sale and has not generated significant revenue to date.
• Ludwig Enterprises has incurred significant net losses: $1,190,387 for the six months ended June 30, 2025, and $3,016,884 for the year ended December 31, 2024.
• The company has a working capital deficit of $3,402,780 and an accumulated deficit of $8,449,753 as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• The proceeds from this offering are not sufficient to conduct proposed clinical trials to completion, requiring additional future funding.
• The company has limited experience in dealing with third-party manufacturers or commercializing proposed product candidates.
• The successful commercialization of products depends on public acceptance of RNA-based products and the regulatory environment for Laboratory-Developed Tests (LDTs) is uncertain, with potential for increased FDA oversight.
• The medical testing products industry is highly competitive, with many larger, more established, and better-capitalized competitors.
• The company's business plan is not based on independent market studies, relying instead on management's experience, judgment, and assumptions.
• Investors in this offering will experience immediate and substantial dilution in net tangible book value, estimated at $ per share based on the assumed offering price.

Risks

• Uncertainty concerning the company's ability to continue as a going concern, which may impair its ability to raise capital.
• Significant losses incurred in prior periods and expected future losses could cause the stock price to decline or materially adversely affect financial condition.
• Dependence on successful completion of capital campaigns; failure to obtain additional capital could require scaling back, delaying, or ceasing operations.
• Reliance on RNA-based molecular biology, with successful commercialization dependent on public perceptions of RNA-based products.
• Potential for FDA to actively regulate tests, incurring substantial costs and delays for premarket clearance/approval and post-market controls.
• Intense competition from larger, more established, and better-capitalized companies in the medical testing products industry.
• Difficulty in obtaining materials for diagnostic tests (e.g., mRNA genetic microarrays) in required quality, quantity, or at projected prices.
• Inability to obtain and maintain protection of intellectual property, which is costly and could reduce product value.
• Risk of litigation and government investigations, which could be expensive and distracting.
• Significant voting power held by principal shareholders (Dr. Marvin S. Hausman, Thomas Terwilliger, Barranquilla Investments, LLC, Vasaio Capital, Inc.) who may take actions not in the best interests of other shareholders.
• The proposed reverse stock split could cause the stock price to decline relative to its pre-split value and decrease liquidity.
• No independent valuation of the stock, meaning the offering price may be speculative and the stock could be worth less than the purchase price.
• Future issuances of debt or equity securities could negatively affect the market price and dilute existing stockholders.
• The company does not intend to pay dividends, meaning investors will only realize a return through stock price appreciation.
• Broad discretion of management in the use of offering proceeds, which may not be used effectively to enhance stockholder value.
• Common Stock is considered a 'penny stock,' subjecting it to restrictions on marketability and potentially reducing trading activity.
• Volatility in trading volume and market price of Common Stock due to various factors, including operating results, competitor actions, and market speculation.
• Costs of being a public company could be significant and may preclude seeking financing on acceptable terms.
• Holding company structure makes the company dependent on subsidiaries for cash flow, subordinating stockholder rights to subsidiary creditors in insolvency.

Future Outlook

The company expects to launch and market its proprietary mRNA genetic testing kits, starting with the Revealia™ Breast test, by the end of the fourth quarter of 2025, assuming it obtains needed funding. It anticipates continued significant operating and capital expenditures for research, marketing, and headcount expansion. The company aims to expand validation through four planned observational studies for various cancers, expected to begin within six months. Long-term success depends on securing reimbursement from commercial insurers and public payors, which is a key driver for adoption.

Management Comments

• "We believe we are the first to employ a non-invasive cheek swab test to collect mRNA samples in quantities sufficient for our intended analyses."
• "Our approach seeks to enable detection of upstream inflammation-driven diseases to support personalized treatment decisions."
• "We intend to launch and market our proprietary mRNA genetic testing kits into the U.S. marketplace by the end of the fourth quarter 2025."
• "We believe that the combination of mRNA genetic expression analysis and machine learning tools can, with a certain degree of accuracy, identify individuals with active breast cancer."
• "Our management believes that building investor awareness of our Company is an important aspect of any company that seeks to uplist its stock to a higher quality market, to benefit its shareholders."
• "We anticipate that the net cash proceeds of this Offering will be used primarily to execute our business plan and will include expenditures for equipment, marketing, staffing, legal expenses, accounting expense, Company awareness, research and clinical trials, debt repayment and the exercise of an option to buy back certain shares of our Common Stock."
• "We anticipate that the proceeds from this offering will increase our existing cash and cash equivalents enough to enable us to maintain our current operations for at least the next 12 months."
• "We believe that the proceeds of this Offering will be enough for us to complete our proposed clinical trials, however, we may need to raise additional funds to complete them and there is no assurance that we will be able to raise the additional funds required to do so."

Industry Context

The company operates in the highly competitive and rapidly evolving medical testing products industry, specifically focusing on genomics-based diagnostics for inflammation-related chronic diseases. The market for cancer diagnostics is substantial, with the U.S. breast cancer diagnostics market projected to reach $3.4 billion by 2030 and the global cancer diagnostics market estimated at $160 billion in 2025. The industry is shifting towards proactive, preventive, and personalized healthcare, creating an unmet need for earlier disease detection tools. Ludwig's mRNA-based approach aims to differentiate itself from traditional DNA-based testing by providing a dynamic, real-time snapshot of disease activity, aligning with consumer demand for convenient, at-home testing solutions.

Comparison to Industry Standards

• The preliminary validation studies for Revealia™ Breast achieved a sensitivity of approximately 92%, specificity of 54%, negative predictive value of 86%, and an AUC of 76%. These results are stated to compare favorably to published benchmarks for mammography, which is a current standard for breast cancer screening.
• The company's non-invasive cheek swab collection method is positioned as more convenient than existing blood, stool, or tear-based tests offered by competitors like Natera (circulating tumor DNA), Guardant Health (blood-based), Exact Sciences (stool-based), GRAIL (blood-based), Freenome (multiomics blood tests), and DELFI Diagnostics (cfDNA fragmentomics).
• Unlike DNA-based testing (e.g., for inherited risk), Ludwig's mRNA approach offers a dynamic, real-time snapshot of disease biology, which is presented as a key differentiator in the cancer diagnostics landscape.
• The company acknowledges that many competitors (Natera, Guardant Health, Exai Bio, Exact Sciences, GRAIL, Freenome Holdings, DELFI Diagnostics, Avantect) possess significantly greater financial, technical, and commercial resources, longer operating histories, greater name recognition, and larger consumer bases.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• Potential for future claims related to business activities, including intellectual property, employment matters, or product safety/efficacy, which could lead to costly litigation and reputational harm.

Related Party Transactions

• Simple promissory note issued to former CEO Charles Todd, Jr. for $36,912 on March 10, 2025, bearing 8% interest, due September 30, 2025.
• Simple promissory note issued to former CEO Jose Antonio Reyes for $5,000 on December 17, 2024, bearing 8% interest, due March 31, 2025 (redeemed in May 2025 for $5,000 principal and $165 accrued interest).
• Common Stock Repurchase Agreement with Worthington Financial Services, Inc. (Worthington) effective August 10, 2023, to repurchase 171,162,746 shares for a promissory note of $122,873 at 8% interest (extended to April 1, 2025).
• IP Agreement on September 16, 2024, with Chief Science Officer Marvin S. Hausman, M.D., and Nova Mentis Life Science Corp., conveying patent rights for an mRNA Neuro Panel and Serotonin Assay. Consideration included forgiveness of $245,712 in consulting fees owed to Dr. Hausman, issuance of 750,000 shares of common stock to Nova, and a 5% royalty on commercialization revenue (2.5% each to Nova and Hausman until Hausman receives $245,712, then 5% to Nova).
• Consulting agreement with Homeopathic Partners, Inc. (terminated September 5, 2023), which previously involved $10,000/month and 10% of gross sales revenues attributable to their efforts.
• Consulting agreement with Dr. Marvin Hausman, M.D. (terminated September 5, 2023), which previously involved $5,000/month and 10% commission on net proceeds from business he generated.
• Corporate World, Inc., owned by former COO Thomas Terwilliger, has served as the company's registered agent in Nevada since February 2006, receiving $350 annually.
• Payments to Thornhill Advisory Group, Inc. (owned by CFO Scott J. Silverman) of $37,500 for the six months ended June 30, 2025, and $22,500 for the six months ended June 30, 2024, for financial advisory services.
• Payments to Jose Antonio Reyes (former CEO) of $0 for the six months ended June 30, 2025, and $11,250 for the six months ended June 30, 2024, for employment services.

Stakeholder Impact

• **Shareholders:** Will experience significant dilution from the public offering and conversion of preferred stock and convertible notes. The proposed reverse stock split could affect stock price and liquidity. Existing shareholders' voting power may be concentrated in principal shareholders. The 'going concern' uncertainty poses a substantial risk to investment value.
• **Employees:** The company plans to increase headcount significantly in the coming years, which could create new employment opportunities. However, the company's financial instability and dependence on capital raises could impact job security if funding is not secured.
• **Customers:** The launch of the Revealia™ Breast test by Q4 2025 could offer a new, non-invasive diagnostic option for breast cancer screening. However, the lack of insurance coverage for home testing kits may be a significant impediment to adoption.
• **Creditors:** Convertible noteholders will see their debt converted to equity upon the offering's effectiveness. Other creditors face risk due to the company's working capital deficit and going concern uncertainty, although some debt will be repaid from offering proceeds.
• **Suppliers/Partners:** The company relies on third-party manufacturers, logistics providers, and CLIA-certified laboratories. Their business could be impacted by the company's financial stability and ability to scale operations.

Next Steps

• Effect a reverse stock split of Common Stock (1-for-50 to 1-for-250) in connection with the public offering.
• Apply to have Common Stock listed on a national exchange under a new symbol.
• Consummate the public offering, contingent on exchange listing approval.
• Launch and market the Revealia™ Breast test into the U.S. marketplace by the end of Q4 2025.
• Commence three separate clinical studies for breast, lung, ovarian, and pancreatic cancers within six months, subject to funding.
• Hire key personnel, including a Chief Marketing Officer, Chief Compliance Officer, and ancillary support staff.
• Implement a direct-to-consumer marketing campaign and company awareness initiatives.
• Expand laboratory infrastructure and secure additional CLIA/CAP certifications.
• Pursue coverage and reimbursement from commercial insurers and public payors for its tests.
• Evaluate other inflammation-driven conditions (cardiovascular, neurodegenerative, metabolic diseases) as longer-term opportunities for platform expansion.
• Potentially license biomarker panels and machine-learning algorithms for pharmaceutical R&D and develop a proprietary mRNA Inflammatory Index database.

Key Dates

Recommendation

Ludwig Enterprises is an early-stage company with no revenue-generating products currently on the market. It has a substantial accumulated deficit of over $8.4 million and a working capital deficit of $3.4 million, leading its independent auditors to express 'substantial doubt about its ability to continue as a going concern.' The proposed public offering is a critical capital raise for survival, not for growth from a position of financial strength. Investors in this offering will face immediate and significant dilution. The company operates in a highly competitive and regulated industry, with numerous risks including regulatory uncertainty for its LDTs, manufacturing complexities, and dependence on future capital that is not assured. Given the severe financial distress, lack of current revenue, high operational risks, and the explicit going concern warning, the investment carries an extremely high risk of capital loss. A 'strong sell' recommendation is warranted as the company's viability is highly uncertain.

Keywords

Genomics, Diagnostics, mRNA Testing, Breast Cancer Screening, SEC Filing, Public Offering, Biotechnology, Medical Devices, LDT, Reverse Stock Split, Capital Raise, Early-Stage Company, Inflammation, Cancer Detection